These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

53 related articles for article (PubMed ID: 20479737)

  • 21. Protective effects of L-dopa and carbidopa combined treatments on human catecholaminergic cells.
    Colamartino M; Padua L; Meneghini C; Leone S; Cornetta T; Testa A; Cozzi R
    DNA Cell Biol; 2012 Nov; 31(11):1572-9. PubMed ID: 23020119
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dietary influence of tyrosine and phenylalanine on the response of B16 melanoma to carbidopa-levodopa methyl ester chemotherapy.
    Meadows GG; Pierson HF; Abdallah RM; Desai PR
    Cancer Res; 1982 Aug; 42(8):3056-63. PubMed ID: 7093952
    [No Abstract]   [Full Text] [Related]  

  • 23. Levodopa therapy in a Lesch-Nyhan disease patient: pathological, biochemical, neuroimaging, and therapeutic remarks.
    Serrano M; Pérez-Dueñas B; Ormazábal A; Artuch R; Campistol J; Torres RJ; García-Cazorla A
    Mov Disord; 2008 Jul; 23(9):1297-300. PubMed ID: 18528895
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Enteral levodopa/carbidopa infusion in advanced Parkinson disease: long-term exposure.
    Nyholm D; Lewander T; Johansson A; Lewitt PA; Lundqvist C; Aquilonius SM
    Clin Neuropharmacol; 2008; 31(2):63-73. PubMed ID: 18382177
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetics and bioavailability of Sinemet CR: a summary of human studies.
    Yeh KC; August TF; Bush DF; Lasseter KC; Musson DG; Schwartz S; Smith ME; Titus DC
    Neurology; 1989 Nov; 39(11 Suppl 2):25-38. PubMed ID: 2685649
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Understanding Parkinson's disease: an update on current diagnostic and treatment strategies.
    Pahwa R
    J Am Med Dir Assoc; 2006 Sep; 7(7 Suppl 2):4-10. PubMed ID: 17948613
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Optimizing levodopa therapy to treat wearing-off symptoms in Parkinson's disease: focus on levodopa/carbidopa/entacapone.
    Reichmann H; Emre M
    Expert Rev Neurother; 2012 Feb; 12(2):119-31. PubMed ID: 22288667
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease.
    Nyholm D; Nilsson Remahl AI; Dizdar N; Constantinescu R; Holmberg B; Jansson R; Aquilonius SM; Askmark H
    Neurology; 2005 Jan; 64(2):216-23. PubMed ID: 15668416
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pramipexole combined with levodopa improves motor function but reduces dyskinesia in MPTP-treated common marmosets.
    Tayarani-Binazir KA; Jackson MJ; Rose S; Olanow CW; Jenner P
    Mov Disord; 2010 Feb; 25(3):377-84. PubMed ID: 20108359
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Interaction between bromocriptine and levodopa. Biochemical basis for an improved treatment for parkinsonism.
    Hutt CS; Snider SR; Fahn S
    Neurology; 1977 Jun; 27(6):503-10. PubMed ID: 577299
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Levodopa/carbidopa intestinal gel infusion long-term therapy in advanced Parkinson's disease.
    Nyholm D; Klangemo K; Johansson A
    Eur J Neurol; 2012 Aug; 19(8):1079-85. PubMed ID: 22360705
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neurochemical and psychomotor interactions of new selective COMT inhibitors with clorgyline and nomifensine in levodopa-treated rats and mice.
    Törnwall M; Tuomainen P; Männistö PT
    Arch Int Pharmacodyn Ther; 1992; 320():5-20. PubMed ID: 1300941
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Loss of central nervous system component of dopaminergic inhibition of prolactin secretion in patients with prolactin-secreting pituitary tumors.
    Fine SA; Frohman LA
    J Clin Invest; 1978 Apr; 61(4):973-80. PubMed ID: 659585
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Patterns of failure following surgical resection for malignant pleural mesothelioma.
    Jänne PA; Baldini EH
    Thorac Surg Clin; 2004 Nov; 14(4):567-73. PubMed ID: 15559064
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Outcome prediction of enteral levodopa/carbidopa infusion in advanced Parkinson's disease.
    Westin J; Nyholm D; Groth T; Dougherty MS; Yerramsetty PK; Palhagen SE
    Parkinsonism Relat Disord; 2006 Dec; 12(8):509-13. PubMed ID: 16731025
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacotherapy: problems and practices.
    Muenter MD
    Clin Neuropharmacol; 1986; 9 Suppl 1():S23-36. PubMed ID: 3708606
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Malignant melanoma and levodopa.
    Rosin MA; Braun M
    Cutis; 1984 Jun; 33(6):572-4. PubMed ID: 6744949
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The chemotherapy of malignant melanoma.
    Wick MM
    J Invest Dermatol; 1983 Jun; 80(1 Suppl):61s-2s. PubMed ID: 20479737
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The chemotherapy of malignant melanoma.
    Wick MM
    J Invest Dermatol; 1983 Jun; 80 Suppl():61s-62s. PubMed ID: 6854056
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sodium ascorbate enhancement of carbidopa-levodopa methyl ester antitumor activity against pigmented B16 melanoma.
    Pierson HF; Meadows GG
    Cancer Res; 1983 May; 43(5):2047-51. PubMed ID: 6831435
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.